At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 404 enrolled

Drug / intervention

AIN457 +3 moredrug

Likely dose

AIN457A 150 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00941031

NCT00941031Phase 2Completed

Compare CT.gov

A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Novartis Pharmaceuticals·interventional·Posted Jul 17, 2009·Updated Aug 20, 2015

In Brief

A Phase 2 clinical trial evaluating AIN457, AIN457A, and 1 other intervention for Chronic Plaque-type Psoriasis. Completed, enrolled 404 participants across 62 sites in 7 countries.

Detailed Summary

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsChronic Plaque-type Psoriasis

CountriesFrance, Germany, Iceland, Israel, Japan, Norway, United States

Collaborators--

Timeline

Phase 2CompletedFinished

20102011201220132014201520162017201820192020202120222023202420252026

Enrollment StartJul 2009

First PostedJul 2009

Primary CompletionDec 2010

TodayJul 2026

First PostedJul 17, 2009

Enrollment StartJul 1, 2009

Primary CompletionDec 1, 2010

TodayJul 2, 2026

Enrollment to primary: 1.4 yearsPosted 17.0 years ago

Interventions

AIN457drug

AIN457Adrug

Induction with monthly injections - "Monthly": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9

AIN457Adrug

Early loading induction - "Early": secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5

Placebodrug

Placebo - "Placebo": Placebo administered at weeks 1, 2, 3, 5, 9